Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Table 2 Comparative safety of IFX SC and VDZ during a 1-year period in patients with ulcerative colitis

Outcome	Group	Events	Total	Proportion (95% CI)	Heterogeneity (I²)
AE	IFX SC	52	78	0.67 (0.56-0.76)	0%
AE	VDZ	350	543	0.64 (0.60-0.68)	44%
SAE	IFX SC	9	78	0.12 (0.06-0.21)	0%
SAE	VDZ	59	543	0.11 (0.09-0.14)	0%
Infection	IFX SC	24	78	0.31 (0.22-0.42)	0%
Infection	VDZ	139	543	0.26 (0.22-0.29)	14%
Serious infection	IFX SC	5	78	0.06 (0.03-0.14)	35%
Serious infection	VDZ	9	489	0.02 (0.01-0.03)	0%
Discontinuation due to AEs	IFX SC	2	78	0.03 (0.01-0.10)	0%
Discontinuation due to AEs	VDZ	31	667	0.05 (0.03-0.07)	0%

AE Adverse event, CI Confidence interval, IFX Infliximab, SAE Serious adverse event, SC Subcutaneous, VDZ Vedolizumab

ISSN: 1471-230X